Xanomeline-Trospium (Cobenfy): The First Antipsychotic in 70 Years That Leaves Dopamine Alone
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Xanomeline-Trospium (Cobenfy): The First Antipsychotic in 70 Years That Leaves Dopamine Alone

A guide to Cobenfy (xanomeline-trospium), the first antipsychotic in roughly 70 years that does not block dopamine: how it works through muscarinic receptors, the EMERGENT-2 numbers, why movement disorders and weight gain are essentially absent, trospium's role and who should see a doctor first.

Xanomeline-Trospium (Cobenfy): The First Antipsychotic in 70 Years That Leaves Dopamine Alone
Cobenfy is the first schizophrenia treatment in roughly 70 years that does not block dopamine receptors, acting on the muscarinic system instead. The movement disorders and weight gain typical of antipsychotics are essentially absent with it. And the key piece of engineering here is not the new molecule — xanomeline is about thirty years old — but a second one, added specifically to quench its side effects without ever entering the brain.

Key points

Xanomeline-trospium (Cobenfy) is a schizophrenia treatment for adults, approved by the FDA in September 2024. For the first time in roughly 70 years it does not block dopamine receptors: the action runs through the muscarinic system.

SituationHow it helpsWhat human studies showed
Schizophrenia in adultseases symptoms without blocking dopamineEMERGENT-2 (Lancet, 2024), 252 participants in an acute exacerbation of schizophrenia, 5 weeks: the PANSS total score fell by 21.2 versus 11.6 points on placebo (difference −9.6; 95% CI −13.9 to −5.2; p<0.0001; effect size 0.61); all secondary endpoints favoured the drug [1]
Movement and metabolic effectsthe movement and metabolic effects typical of the class are essentially absentextrapyramidal symptoms 0% versus 0% on placebo, akathisia 1% versus 1%, weight gain 0% versus 1%, somnolence 5% versus 4% [1]
Long-term usethe effect holds52-week open-label extension (Am J Psychiatry, 2026): efficacy and the safety profile hold across a year [2]

How it helps

Seventy Years of One Idea

In the 1950s it emerged that the substances easing psychosis blocked dopamine D2 receptors. The dopamine hypothesis of schizophrenia grew out of that observation, and with it every generation of antipsychotics from the first agents to the modern ones.

The approach works. But dopamine is involved in far more than psychosis, and blockade hits all of its functions at once. Hence the familiar catalogue: movement disorders (rigidity, tremor, akathisia), raised prolactin, weight gain and metabolic shifts, sedation and blunted emotion.

It is the side effects, not a lack of efficacy, that most often make a patient abandon treatment. And abandoned treatment in schizophrenia means relapse.

A Different Way Into the Same System

Xanomeline acts on the muscarinic acetylcholine receptors, primarily the M1 and M4 subtypes. They sit in the same brain circuits involved in psychosis, but they govern those circuits from another side.

Simplified: activating M4 indirectly reduces excessive dopamine transmission where it is excessive, instead of blocking receptors outright everywhere. The difference is roughly that between muffling a loudspeaker and turning the signal down at the input.

Why This Drug Sat on a Shelf for Thirty Years

The striking part of the story is that xanomeline is not a new molecule. It was tested back in the 1990s in Alzheimer's disease. It worked: patients' psychotic symptoms eased. But muscarinic receptors exist throughout the body, and the drug activated all of them — nausea, vomiting, sweating, salivation, cramps. Tolerability proved unacceptable and development was halted.

The solution found two decades later was not chemical but engineering. Trospium was added: a substance that blocks the very same muscarinic receptors but barely crosses the blood-brain barrier.

XanomelineTrospium
What it doesActivates muscarinic receptorsBlocks muscarinic receptors
Where it actsBrain and bodyEssentially body only
What it is forThe therapeutic effectQuenching the other's side effects
Crosses into the brainYesEssentially no

What This Changes In Practice

For a patient who has lived for years with an antipsychotic and paid for it in rigidity, extra weight and constant drowsiness, a drug with a different set of problems is not a cosmetic improvement. Intolerance is what destroys treatment most often.

How it is prescribed

Any prescription, and any change of therapy, is a psychiatrist's decision.

▸ Replacing working therapy carries its own risk of relapse, so the reason to discuss a switch is intolerance of the current regimen, not novelty as such.
▸ Blood pressure monitoring is part of follow-up.

Who should see a doctor first

Side effects. The set of side effects has moved — out of neurology and metabolism, into the digestive system [1]:

Adverse eventCobenfyPlacebo
Nausea19%6%
Vomiting14%1%
Constipation21%10%
Dyspepsia19%8%
Raised blood pressure10%1%

In a pooled analysis of the five-week trials (J Clin Psychiatry, 2025), the gastrointestinal effects were mostly mild to moderate, arose early in treatment and eased over time [3].

Who It Is Not For

▸ Patients with significant gastrointestinal problems: that is the system carrying the load.
▸ In urinary retention, certain forms of glaucoma and other states where an anticholinergic component is contraindicated.
▸ Anyone whose current therapy works and is well tolerated: changing it without cause is risk without gain.
▸ As self-medication or a self-directed switch — changing an antipsychotic is done only under supervision.

Bottom Line

▸ The first mechanism in ~70 years in schizophrenia that does not rest on dopamine blockade.
▸ An engineering solution: an old molecule was rescued by a second one that quenches its side effects without entering the brain.
▸ Efficacy confirmed: PANSS −21.2 versus −11.6 on placebo, effect size 0.61.
▸ Movement disorders and weight gain are essentially absent — the key clinical distinction.
▸ What to keep in mind — nausea, vomiting, constipation and raised blood pressure markedly more often than on placebo.

Treatment can be discussed at a consultation; the drug can be ordered here.

References

1. Kaul I, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403(10422):160–170. PMID 38104575

2. Kaul I, et al. Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial. Am J Psychiatry. 2026;183(3):183–192. PMID 41634905

3. Kaul I, et al. Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials. J Clin Psychiatry. 2025;86(1). PMID 40047530

4. COBENFY (xanomeline and trospium chloride) — US Prescribing Information, Bristol Myers Squibb.

Source: Xanomeline-Trospium (Cobenfy): The First Antipsychotic in 70 Years That Leaves Dopamine Alone — universum.earth. Dr. Pereligyn.

Come back
Request a call back